Cancer remains the second most common cause of death in the US, accounting for nearly 1 out of every 4 deaths. In recent years, several varieties of nanoparticles (NPs) have been synthesized with the intent of being utilized as tumor drug delivery vehicles. We have produced superparamagnetic, gold-coated magnetite (Fe3O4@Au) NPs and loaded them with the chemotherapeutic drug doxorubicin (DOX) for magnetic drug targeting of tumors. The synthetic strategy uses the food thickening agent gellan gum (Phytagel) as a negatively charged shell around the Fe3O4@Au NP onto which the positively charged DOX molecules are loaded via electrostatic attraction. The resulting DOX-loaded magnetic nanoparticles (DOX-MNPs) were characterized using transmission electron microscopy (TEM), energy dispersive xray spectroscopy (EDS), superconducting quantum interference device (SQUID) magnetometry, surface area electron diffraction (SAED), zeta potential (ZP) measurements, fourier transform infrared spectroscopy (FTIR) as well as UV/Vis and fluorescence spectroscopy. Cytotoxicity of the DOX-MNPs was demonstrated using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay on C6 glioma cells. Cellular uptake of DOX-MNPs was enhanced with magnetic fields, which was quantitatively determined using flow cytometry. This improved uptake also led to greater tumor cell death, which was measured using MTT assay. These magnetic drug targeting results are promising for a new therapy for cancer.
Introduction
Cancer is the second most common cause of death in the US, exceeded only by heart disease. Cancer research has been successful as in decreasing in overall death rates between 1991 and 2010, by about 20% in both men and women 1 . The cancer treatment protocol for most cancers requires chemotherapy.
Unfortunately most chemotherapeutic agents exhibit poor specificity in reaching tumor tissue in addition to dose-limiting toxicity. As a result, many patients experience adverse side effects due to the administered chemotherapy treatments.
New drug delivery strategies are being developed to improve efficacy of cancer patient treatments, while minimizing systemic toxicity. One promising treatment involves using NPs as a means of targeting cytotoxic drugs to specific tumor cells and tissue, thereby limiting systemic exposure. Typically in the use of NPs for the purpose of drug therapy, the drug is dissolved, entrapped, encapsulated, or attached to the NPs. The major goals in the design of NPs for drug delivery include: (i) control of particle size, (ii) variation of surface properties, and (iii) ability to release of pharmacologically active agents to achieve the site-specification of the drug at the therapeutically optimal rate and dose regimen. Novel NP-based applications for cancer treatments are being explored because of their ability to (i) decrease toxicity and the occurrence of adverse reactions, (ii) utilize drug more effectively, (iii) control the rate and site of drug release, (iv) provide a more predictable drug delivery system [2] [3] [4] Currently, there are two different types of targeting utilized by scientists studying NP drug delivery systems for cancer. Passive targeting exploits the enhanced permeability and retention (EPR) effect that is defined by leaky vasculature around tumors caused by tumor-induced angiogenesis with incomplete endothelial cell junctions, resulting in the accumulation of the NPs at the tumor site 5 . This passive targeting strategy has been shown to be an efficient method to reduce the toxic side effects and increase the therapeutic index of drug molecules 6, 7 . Active targeting usually involves attaching ligands on the surface of NPs, which bind to over-expressed receptors on tumor cells. Targeting specific surface receptor causes selective uptake of NPs by the cancer cells 8 . Active targeting may also involve utilizing physical stimuli for actively localizing NPs to the target site, including temperature, pH, electric charge, light, sound and magnetism 9, 10 . Our research aims at utilizing magnetism as a physical stimulus, for efficient targeting of target specific cells.
Magnetic Drug Targeting (MDT) involves binding tumor drugs to biocompatible magnetic nanoparticles (MNPs), which can be guided to specific tumor sites via magnetic fields. The magnetic field can be controlled by magnets placed outside the body and/or by using magnetizable implants inside the body 11 . 42, 43 . The positively-charged amine groups of DOX molecules are electrostatically attracted to the negatively-charged gellan gum surface, which resulted in the final DOX-MNPs.
We also describe the efficacy of our DOX-MNPs to kill glioma cells, and the enhancement in their cellular uptake in the presence of a static magnetic field. Increased endocytosis of plain MNPs via magnetic fields has been previously observed, especially to overcome the hurdle of gene delivery across cell membranes [44] [45] [46] [47] [48] . In this paper, we show an elevated level of cellular uptake of the tumor drug loaded
MNPs and consequently, increased drug efficacy and cell death caused by the presence of magnetic fields. This enhancement makes our drug vehicle an ideal candidate for MDT. The targeting and augmented cellular uptake using magnetic fields via our DOX-MNPs can be used to target DOX to specific tumor sites, and thus improve efficacy in vivo. NanoDrop 1000 UV-Vis spectrophotometer and NanoDrop 3300 Fluorimeter.
Materials and Methods
All chemicals were purchased from Sigma-Aldrich® with the exception of DOX (LC Laboratories®) and hydrogen tetrachloroaurate (III) hydrate (Alfa Aesar ®).
Synthesis of Gold-Coated Magnetite Nanoparticles (Fe3O4@Au NP)
The Fe3O4@Au NPs were synthesized by a coprecipitation technique, described in Mandal et al. (2005) and various other articles 34, 49 , using ferrous and ferric salts to form Fe3O4. These Fe3O4 cores were then coated with a layer of gold by a surface adsorption technique. The detailed procedure is given below.
Iron Stock Solution Preparation and then heated to 75°C in a water bath. 25 ml of the iron stock solution was added dropwise using a syringe into this solution under vigorous non-magnetic stirring. After complete addition of the stock solution, the stirring was continued for 20 minutes. During the entire procedure, the temperature of the water bath was maintained at 75 °C. The Fe3O4 magnetic cores obtained and were allowed to settle before magnetic separation to remove the supernatant. The particles obtained were then washed multiple times with water to remove the excess surfactant. These cores were then resuspended in distilled water.
Fe3O4 Nanoparticle Coating with Gold (Au)
A solution containing the prepared Fe3O4 cores and hydrogen tetrachloroaurate (III) hydrate was taken in a 1:2 molar ratio. In addition, 0.5 g of D(+)-glucose was added to the solution followed by sonication for 15 minutes. This solution was then heated in the water bath at 50-60 o C for 1 hour while stirring slowly.
The NP solution changed to a brown-red color during the coating process. The solution was vortexed, followed by subsequent magnetic separation and washed several times before being resuspended in water.
Conjugation of DOX to Fe3O4@Au NP via Gellan Gum
An aqueous solution of gellan gum (Phytagel TM ) was prepared by slow addition of 5 mg of Phytagel TM to 90 ml of water while heating using a magnetic stirring hotplate. Water was added till the solution volume reached 100 ml. The pH of the solution was adjusted to 10 by dropwise addition of 0.16 M NaOH solution. The solution was heated to 70 o C while being stirred. After removing from heat, 1.6 mL of 40 mg/ml Fe3O4@Au NP solution was added dropwise to the gellan gum solution while it was being nonmagnetically stirred. The solution was cooled to room temperature and stirred for 1 hour. The Fe3O4@Au NPs were recovered using magnetic decantation and washed 3-4 times with distilled water. In a dark room, 3.0 mg of DOX was dissolved in 1 mL of nanopure water, which was then added dropwise to the Au@Fe3O4-GG NP solution, while it was being stirred slowly. The solution was stirred nonmagnetically for 24 hours. The resulting DOX-MNPs were magnetically decanted and washed several times with water. The DOX-MNPs were then resuspended in water to a concentration of 40 mg/ml.
Estimation of loading of DOX on the Fe3O4@Au-GG nanoparticles
A known weight of DOX was added to an aqueous dispersion of Fe3O4@Au-GG NPs of known volume and concentration. This was then stirred for 24 hours in the dark. The DOX-MNPs formed were magnetically decanted and the supernatant was collected. Weight of DOX in the supernatant was determined by both UV absorbance and well as drying/weighing it.
The percentage loading of DOX was calculated by using the formula shown in equation 1: 
Results

Synthesis and Characterization
TEM, EDS and SQUID magnetometry results of Fe3O4@Au NPs
The Fe3O4@Au NPs were characterized using TEM, EDS and SQUID magnetometry. A histogram showing the size distribution of the Fe3O4@Au NPs is given in figure 1A , which indicates that most of the Fe3O4@Au NPs have a diameter of 20-25nm. A particle with this diameter range was found to have a magnetite core of 8-12 nm, with a uniform gold shell thickness of 8-15 nm ( figure 1B,C) .
The gold coating on the magnetite core serves two purposes: (i) It prevents the oxidation of the Fe3O4 core into maghemite (Fe2O3) by forming an inert biocompatible protective coating layer. Maghemite is found to be less magnetically susceptible than magnetite 50, 51 (ii) It also forms an excellent platform for conjugating drugs to the NP surface. Due to the variability in the size of the DOX-MNPs, there is a possibility that they are multi-core particles rather than single core particles, or a mixture of both types. Encapsulation of magnetic cores using a polymer matrix can result in multi-core particles 68 , which is similar to our synthesis procedure. The positive zeta potential of Fe3O4@Au NPs, +11.6, decreases to -27.3 after coating with the negatively charged gellan gum. After loading the positively charged DOX molecules, the zeta potential increases to -15.4, confirming DOX loading. The conjugation of DOX to the vehicle was also confirmed by using fluorescence microscopy. As DOX is a fluorescent molecule, DOX-MNPs fluoresce, emitting a red color (at 590 nm) when compared to Fe3O4@Au NPs (figure 3B).
Zeta potential measurements
Fourier Transform Infrared (FTIR) spectroscopy results
Loading of the DOX molecules to the NP was also confirmed using FTIR spectroscopy. Figure 4A shows the FTIR spectra of the Fe3O4@Au-GG NPs. The presence of the gellan gum polymer on the Fe3O4@Au NP surface is indicated by the presence of a broad O-H peak at 3400 cm -1 , glycosidic bonds are indicated by the peak at 1640 cm -1 , C-H bending peak at 1409 cm -1 and C=C bond at 1500 cm -1 . Figure 4B shows the FTIR spectra of the DOX-MNPs (blue) superimposed on the free DOX solution spectra (red). Both spectra were found to have regions with similar peaks (circled in pink in figure 4B ) with the same x-axis (cm -1 ) values. This confirms the presence of DOX on the DOX-MNP surface. 
Absorption and Fluorescence Emission Spectra
The stability of DOX molecules after loading on Fe3O4@Au-GG NPs was studied by using fluorescence and UV-Vis spectroscopy. The absorption/excitation spectra of free DOX and DOX-MNPs (green and brown lines respectively in Figure 5A ) indicate that both have an absorption maximum at 480 nm. The emission spectra of DOX in solution and DOX-MNPs were recorded from 500 to 700 nm at a fixed excitation wavelength of 480 nm; the spectra recorded are shown in Figure 5B . There was no change in the spectral profile of DOX-MNPs when compared to DOX molecules, and the emission peak at 597 nm was retained. respectively. Figure 6 shows the confocal microscopy images that confirm DOX-MNPs were taken up into the cells.
DOX loading efficiency
The DOX loading efficiency on the Fe3O4@Au-GG NPs was determined to be 70% using the procedure mentioned in § 3.3. Our measurements showed that 1mg of Fe3O4@Au-GG NPs contain 0.31 mg of DOX loaded on its surface, resulting in the final DOX-MNPs.
DOX-MNP efficacy studies
MTT assay results 
Discussion
In this paper, we synthesized a tumor drug delivery platform for magnetic targeting. A magnetite core, was synthesized to enable active targeting using an external magnetic field. The core was coated with a gold shell to form Fe3O4@Au NPs. The gold shell facilitated loading of DOX molecules to its surface by The individual components of the delivery vehicle are not toxic: gold, Fe3O4 and the gellan gum polymer are biocompatible. Fe3O4 degrades into its components which are integrated in normal iron homeostasis in the body 56, 57 . Gold is a stable unreactive metal, which has been used in several NP based drug formulations 58, 59 . Gellan gum is a bacterial anionic deacetylated sugar polysaccharide secreted by
Pseudomonas elodea that has been found to be biodegradable and biocompatible 51, 60 .
Due to the variability in the size of the DOX-MNPs, there is a possibility that they are multi-core particles rather than single core particles, or a mixture of both types. Both hydrogen bonding and Vanderwall's forces are involved in the formation of the gellan gum matrix structure that encapsulates the magnetic core(s) 69 . Due to the superparamagnetic nature of the individual Fe3O4@Au cores, the multi-core particles are also superparamagnetic, and this does not affect the particle's ability to deliver therapeutic molecules.
Similar experiments conducted by other researchers have also concluded no loss of in the fast relaxation time of SPIONs after being entrapped as multi-core particles in a polymer shell 68 . Therefore, these particles can be successfully used for magnetic drug targeting in tumor treatment.
Synthesis parameters such as temperature, reagent concentrations, surfactant concentrations and stirring speed can affect the sizes of multi-core particles. Production of multi-core particles with good control of the number of magnetic cores per particle, and of the degree of polydispersity of the core sizes, remains a difficult task 70 . One of the main factors that we have attempted to optimize is the amount of gellan gum added to the system. Other papers, such as Dhar et al used smaller quantity of gellan gum (0.02% w/v) to reduce and cap their gold NPs 50,51 . In our gellan gum coating protocol, we used a 5% w/v solution to accommodate for the larger size of our Fe3O4@Au NPs. The amount of gellan gum added to the system was adjusted to obtain maximum DOX conjugation on the surface of the NP, while maintaining an adequate particle size for drug delivery purposes. As per the data from our histogram (figure 2), 81% of our DOX-MNPs have a mean diameter of around 100 nm. This size is suitable for both systemic and IT delivery.
Confocal microscopy was used to confirm cellular uptake and nuclear localization of the DOX-MNPs.
According to Figure 6 , the DOX-MNPs were successfully endocytosed into the C6 glioma cells, and the z-stack image of the nucleus (stained blue by DAPI) clearly shows co-localization with the DOX molecules (red), which is also the site of therapeutic action for DOX.
FTIR spectroscopy was also used to confirm loading at every step of the synthesis. From the emission spectra, we inferred that the fluorescence signature of DOX is preserved after conjugation on the Fe3O4@Au-GG NP surface. Therefore, the DOX molecular structure is retained following loading on the MNPs, which is important for its biological activity.
The efficacy of DOX-MNPs to kill tumor cells was determined by using MTT assay. Cell viability graphs
showed that DOX-MNPs killed tumor cells, even over short incubation periods (1.5 hours), when a magnetic field is present. The efficacy to kill cells under the influence of a magnetic field, was more pronounced in greater DOX-MNP concentration experiments, which indicates that this effect is due to increased endocytosis of DOX-MNPs into the C6 glioma cells. Any aggregation of the DOX-MNPs, which might have been caused by application of the external magnetic field, did not adversely affect its endocytosis and more importantly, the tumor drug efficacy.
The enhanced DOX-MNP uptake in the presence of magnetic field was also qualitatively and quantitatively determined using TEM and flow cytometry respectively. The TEM images indicated increased destruction of C6 glioma cells in the presence of a magnetic field. Flow cytometry clearly quantified the enhancement in both the cellular uptake ratio and the DOX-MNP uptake due to the magnetic field.
We believe that the increased transfection in the presence of magnetic fields can be attributed to the magnetization of the NPs as well as an additional attractive force (direction of arrow in figure 8A ) generated by the magnetic field, which enhances their translocation through the cell membrane 61 . This force augments the transport velocity of MNPs (in addition to the gravitational force). The velocity of the particle in the magnetic field (Umag) depends on the volume of the magnetic material (Vmag), the hydrodynamic radius (r), and the magnetic field gradient (dB/dz) as shown in equation 1.
= 12 * (1)
Here, M is the magnetic field strength and  is the viscosity of the cell growth medium.
It has been shown that larger MNPs are more easily taken up by cells [62] [63] [64] [65] . However, for efficient steering of NPs in MDT, the NPs need to be superparamagnetic without possessing remnant magnetization on removal of the steering field 66 . This property requires very small MNPs with a magnetic core diameter of around 20 nm 67 . When using smaller MNPs that need to deliver the payload before being cleared from the body, an additional force can be deployed to enhance transfection into the target cells. This work shows that magnetic fields that are used for guidance in the MDT process have the additional beneficial effect of enhancing cellular uptake of drug conjugated superparamagnetic NPs. Magnetically enhanced transfection efficiency of DOX-MNPs, in the presence of magnetic fields is a promising effect for future in vivo MDT studies for treatment of cancer.
Conclusion
In conclusion, our results demonstrate adequate physicochemical properties of our biocompatible custom- superparamagnetic NPs has the ability to potentiate efficacies, improve kinetics and dose response profiles of drugs along with site specific delivery by application of magnetic fields.
